Zenith Capital Corp. (ZHCLF)

OTCMKTS · Delayed Price · Currency is USD
0.0001
-0.0999 (-99.90%)
Apr 25, 2025, 4:00 PM EDT
-99.95%
Market Cap 15.26M
Revenue (ttm) n/a
Net Income (ttm) -7.68M
Shares Out 152.56M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,914
Average Volume 2,866
Open 0.1000
Previous Close 0.1000
Day's Range 0.0001 - 0.1000
52-Week Range 0.0001 - 0.7000
Beta -144.61
RSI 40.38
Earnings Date Apr 4, 2025

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as advanced or metastatic triple negative breast cancer in collaboration with Pfizer Inc. It has research and development collaboration agreement with National Cancer Institute, and licensing agreement with Newsoar... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol ZHCLF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.